摘要
Background: Previously, we reported the efficacy of Lichtena - a phytocosmetic cream product- in atopic dermatitis (AD). Later, fraudulent triamcinolone acetonide (TACA) was detected at low doses (16- 40 μ g/g) in Lichtena. This suggested that TACA may be effective at much lower concentrations than used in commercial products (1,000 μ g/g). Objectives: To investigate the efficacy in AD of low- dose TACA in Lichtena compared to plain Lichtena. Methods: Fourteen patients presenting symmetrical lesions of AD were treated for 1 month with Lichtena plus 25 μ g/g TACA(= verum) and plain Lichtena (= placebo). The severity of the lesions was assessed by the Severity Scoring of Atopic Dermatitis (SCORAD) on days 0 (= baseline), 7, 14 and 28. Results: Already after 1 week of treatment, significant SCORAD differences to baseline were observed comparing verum- and placebo- treated areas. No improvementwas observed using plain Lichtena. Conclusions: TACA displayed a significant improvement of AD at doses up to 40 times lower than in commercial products.
Background: Previously, we reported the efficacy of Lichtena - a phytocosmetic cream product- in atopic dermatitis (AD). Later, fraudulent triamcinolone acetonide (TACA) was detected at low doses (16- 40 μ g/g) in Lichtena. This suggested that TACA may be effective at much lower concentrations than used in commercial products (1,000 μ g/g). Objectives: To investigate the efficacy in AD of low- dose TACA in Lichtena compared to plain Lichtena. Methods: Fourteen patients presenting symmetrical lesions of AD were treated for 1 month with Lichtena plus 25 μ g/g TACA(= verum) and plain Lichtena (= placebo). The severity of the lesions was assessed by the Severity Scoring of Atopic Dermatitis (SCORAD) on days 0 (= baseline), 7, 14 and 28. Results: Already after 1 week of treatment, significant SCORAD differences to baseline were observed comparing verum- and placebo- treated areas. No improvementwas observed using plain Lichtena. Conclusions: TACA displayed a significant improvement of AD at doses up to 40 times lower than in commercial products.
